DelveInsight’s “HER2-Negative Metastatic Breast Cancer Market Insights, Epidemiology, and Market Forecast–2034” report delivers a comprehensive evaluation of the disease landscape, including historical and projected epidemiological trends as well as market dynamics across the United States, EU4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan.
To explore detailed insights related to market outlook, therapy adoption, treatment patterns, and epidemiology trends, visit the HER2-Negative Metastatic Breast Cancer Market Forecast @ https://www.delveinsight.com/sample-request/her2-negative-metastatic-breast-cancer-market
Key Highlights from the HER2-Negative Metastatic Breast Cancer Market Report
- The HER2-Negative Metastatic Breast Cancer market is projected to expand at a notable compound annual growth rate (CAGR) during the forecast period from 2020 to 2034.
- In January 2025, Genentech reported that its Phase III clinical trial evaluating Itovebi reached an important oncology milestone by demonstrating improved overall survival (OS) in certain metastatic breast cancer patients while also delaying disease progression. Results from the randomized double-blind study (NCT04191499) showed that Itovebi, also known as inavolisib, produced statistically significant and clinically meaningful OS improvements when administered with Ibrance (palbociclib) and Faslodex (fulvestrant). These benefits were observed specifically in patients with PIK3CA-mutated, hormone receptor-positive (HR-positive), and HER2-negative metastatic breast cancer.
- According to the Global Cancer Observatory (2020), approximately 253,465 new breast cancer cases were reported in the United States in 2020.
- Data from the Surveillance, Epidemiology, and End Results (SEER) program indicate that more than 200,000 women in the United States are diagnosed with breast cancer annually.
- The Global Cancer Observatory (2020) also reported that Germany, France, Italy, Spain, and the United Kingdom collectively recorded about 69,697 new breast cancer cases in 2020.
- Leading companies involved in the HER2-Negative Metastatic Breast Cancer treatment landscape include Genentech, Inc., AstraZeneca, Merck Sharp & Dohme LLC, Gilead Sciences, BeiGene, Eisai Inc., Novartis Pharmaceuticals, Adagene Inc., Jiangsu HengRui Medicine Co., Ltd., Pfizer, Novartis, CytomX Therapeutics, Tyme Inc., Puma Biotechnology, Inc., G1 Therapeutics, Inc., Context Therapeutics Inc., and others.
- Prominent therapies being investigated or used in the HER2-Negative Metastatic Breast Cancer space include Paclitaxel, Doxorubicin, AZD9833, Pembrolizumab, TF2-68 Ga-IMP-288, BGB-290, Eribulin, Dapagliflozin, ADG106, Famitinib Malate, Talazoparib Tosylate, Letrozole, CX-2009, SM-88, Neratinib, G1T38, Onapristone, and several additional treatment candidates.
- Epidemiological assessments indicate that HER2-Negative Metastatic Breast Cancer predominantly occurs among older women.
- The market for HER2-Negative Metastatic Breast Cancer is anticipated to witness strong expansion during the forecast period, driven by the growing prevalence of the disease and rising awareness. Additionally, the introduction of innovative pipeline therapies across various development stages is expected to significantly reshape the competitive and treatment landscape.
HER2-Negative Metastatic Breast Cancer Overview
HER2-Negative Metastatic Breast Cancer refers to breast cancer that has spread beyond the breast and nearby lymph nodes to distant organs and does not exhibit overexpression of the human epidermal growth factor receptor 2 (HER2) protein. Because HER2 is not overactive in these tumors, HER2-targeted treatments such as trastuzumab are generally ineffective. Treatment approaches often rely on hormonal therapies, chemotherapy, or immunotherapy, depending on the patient’s hormone receptor status, such as HR-positive or triple-negative disease. The absence of HER2 expression plays a crucial role in determining prognosis as well as guiding therapeutic strategies.
Request a Free Sample of the HER2-Negative Metastatic Breast Cancer Market Report @ https://www.delveinsight.com/sample-request/her2-negative-metastatic-breast-cancer-market
HER2-Negative Metastatic Breast Cancer Epidemiology
The epidemiology section of the report offers comprehensive insights into historical, current, and projected epidemiological patterns across the seven major markets (7MM) from 2020 to 2034. It helps identify the drivers of current and future trends by examining numerous clinical studies and expert opinions from key opinion leaders. This section also includes a detailed evaluation of the diagnosed patient pool and projected changes in patient demographics.
HER2-Negative Metastatic Breast Cancer Epidemiology Segmentation
The report presents a detailed epidemiological assessment for the period 2020–2034 across the seven major markets, segmented into:
- Total prevalence of HER2-Negative Metastatic Breast Cancer
- Prevalent cases categorized by disease severity
- Gender-specific prevalence patterns
- Diagnosed cases of episodic and chronic HER2-Negative Metastatic Breast Cancer
To learn more about the factors influencing epidemiology trends, download the HER2-Negative Metastatic Breast Cancer Epidemiology Forecast @ https://www.delveinsight.com/sample-request/her2-negative-metastatic-breast-cancer-market
HER2-Negative Metastatic Breast Cancer Drug Uptake and Pipeline Development
The drug uptake section examines how rapidly newly introduced therapies are being adopted in the HER2-Negative Metastatic Breast Cancer market and evaluates potential treatments expected to launch during the study timeframe. The analysis includes market uptake by individual drugs, therapy-based patient adoption trends, and projected sales performance.
Additionally, the therapeutic assessment identifies treatments expected to achieve rapid market penetration and analyzes the factors contributing to their adoption. The section also provides comparative insights based on market share.
The report further reviews ongoing pipeline development activities, offering insights into therapeutic candidates in various stages of development and the companies leading their advancement. It also highlights recent industry developments, including collaborations, mergers, acquisitions, licensing agreements, and patent activities related to emerging therapies.
Key HER2-Negative Metastatic Breast Cancer Therapies and Companies
- Paclitaxel — Dana-Farber Cancer Institute
- Doxorubicin — Genentech, Inc.
- AZD9833 — AstraZeneca
- Pembrolizumab — Merck Sharp & Dohme LLC
- TF2-68 Ga-IMP-288 — Gilead Sciences
- BGB-290 — BeiGene
- Eribulin — Eisai Inc.
- Dapagliflozin — Novartis Pharmaceuticals
- ADG106 — Adagene Inc.
- Famitinib Malate — Jiangsu HengRui Medicine Co., Ltd.
- Talazoparib Tosylate — Pfizer
- Letrozole — Novartis
- CX-2009 — CytomX Therapeutics
- SM-88 — Tyme Inc.
- Neratinib — Puma Biotechnology, Inc.
- G1T38 — G1 Therapeutics, Inc.
- Onapristone — Context Therapeutics Inc.
Explore additional insights on therapies expected to capture significant market share in the HER2-Negative Metastatic Breast Cancer Treatment Market @ https://www.delveinsight.com/sample-request/her2-negative-metastatic-breast-cancer-market
Scope of the HER2-Negative Metastatic Breast Cancer Market Report
- Study Period: 2020–2034
- Geographical Coverage: 7MM including the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
- Key Companies: Genentech, Inc., AstraZeneca, Merck Sharp & Dohme LLC, Gilead Sciences, BeiGene, Eisai Inc., Novartis Pharmaceuticals, Adagene Inc., Jiangsu HengRui Medicine Co., Ltd., Pfizer, Novartis, CytomX Therapeutics, Tyme Inc., Puma Biotechnology, Inc., G1 Therapeutics, Inc., Context Therapeutics Inc., and others.
- Key Therapies: Paclitaxel, Doxorubicin, AZD9833, Pembrolizumab, TF2-68 Ga-IMP-288, BGB-290, Eribulin, Dapagliflozin, ADG106, Famitinib Malate, Talazoparib Tosylate, Letrozole, CX-2009, SM-88, Neratinib, G1T38, Onapristone, and others.
- The report includes an evaluation of currently marketed treatments as well as emerging therapies in development.
- It also analyzes key market dynamics, including growth drivers and potential barriers impacting market expansion.
- Competitive intelligence assessments within the report cover SWOT analysis, PESTLE analysis, Porter’s Five Forces framework, BCG Matrix, and potential market entry strategies.
- Furthermore, the study highlights unmet medical needs, expert insights from key opinion leaders, analyst perspectives, and reimbursement as well as market access considerations.
To explore more about companies involved in developing therapies for HER2-Negative Metastatic Breast Cancer, visit HER2-Negative Metastatic Breast Cancer Clinical Trials and Therapeutic Assessment @ https://www.delveinsight.com/sample-request/her2-negative-metastatic-breast-cancer-market
Table of Contents
- Introduction to the HER2-Negative Metastatic Breast Cancer Market Report
- Executive Summary
- SWOT Analysis of HER2-Negative Metastatic Breast Cancer
- Patient Share (%) Overview
- Market Overview Snapshot
- Disease Background and Overview
- Epidemiology and Patient Population Analysis
- Country-Specific Patient Population Insights
- Current Treatment Practices and Medical Approaches
- Unmet Medical Needs
- Emerging Therapies
- Market Outlook
- Country-Wise Market Analysis (2020–2034)
- Market Access and Reimbursement Analysis
- Market Drivers
- Market Barriers
- Appendix
- Report Methodology
- DelveInsight Capabilities
- Disclaimer
- About DelveInsight
About DelveInsight
DelveInsight is a prominent healthcare business consulting and market research firm specializing in the life sciences sector. The company assists pharmaceutical and biotechnology organizations by delivering comprehensive end-to-end market intelligence solutions aimed at improving strategic performance.
DelveInsight also provides specialized healthcare consulting services that support companies in conducting detailed market analysis, enabling them to accelerate business growth and address industry challenges through data-driven and practical strategies.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting